



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,662	01/11/2002	Andreas Jordan	1214.00026	9966
7590 05/27/2008 Wood Phillips Van Santen Clark & Mortimer 500 West Madison Street Suite 3800 Chicago, IL 60661			EXAMINER CANELLA, KAREN A	
			ART UNIT 1643	PAPER NUMBER
			MAIL DATE 05/27/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**Supplemental
Notice of Allowability**

Application No.

09/914,662

Examiner

Karen A. Canella

Applicant(s)

JORDAN, ANDREAS

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERIT IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to The Printer Query of April 12, 2008.
2. ☒ The allowed claim(s) is/are 1-3, 6, 7, renumbered as 1-5, respectively.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date ____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date ____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date ____
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other ____.

/Karen A Canella/
Primary Examiner, Art Unit 1643

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark Polyakov on May 22, 2008.

The application has been amended as follows:

In the specification:

The paragraph on page 4, lines 15-23 has been replaced with the following:

The proposed method is advantageously supplemented for the further perfection of the invention by a medium suitable for very small amounts of tissue composed of inorganic salts, specifically: $\text{Ca}(\text{NO}_3)_2$ 10-100 mg/L, $\text{CaCl}_2 \cdot \text{H}_2\text{O}$ 80-150 mg/L, KCl 200-1000 mg/L, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 200-700 mg/L, NaCl 3000-10000 mg/L, NaHCO_3 1500-4000 mg/L, Na_2HPO_4 100-1000; amino acids, specifically: L-Arginine-4HCl 10-500 mg/L, L-Asparagine (free base) 10-500 mg/L, L-Aspartic Acid 10-500 mg/L, L-Cystine 10-500 mg/L, L-Glutamic Acid 10-500 mg/L, L-Glutamine 10-500 mg/L, Glycine 10-500 mg/L, L-Histidine (free base) 10-500 mg/L, L-Hydroxyproline 10-500 mg/L, L-Isoleucine 10-500 mg/L, L-Leucine 10-500 mg/L, L-Lysine-HCl 10-500 mg/L, L-Methionine 10-500 mg/L, L-Phenylalanine 10-500 mg/L, L-Proline 10-500 mg/L, L-Serine 10-500 mg/L, L-Threonine 10-500 mg/L, L-Tryptophane 5-400 mg/L, L-Tyrosine 10-500 mg/L, L-Valine 10-500 mg/L, L-Alanine 10-300 mg/L; vitamins, specifically: Biotin 0,01-10 mg/L, D-Ca-Pantothenate 0,01-10 mg/L, Choline Chloride 0,1-50 mg/L, Folic Acid 0,01-10 mg/L, i-Inositol 0,1-100 mg/L, Niacin Amide 0,01-10 mg/L, Pyridoxine-HCl 0,01-10 mg/L, Riboflavin 0,1-100 ug/L, Thiamine HCl 0,1-50 mg/L, Para-Aminobenzoic Acid 1-1000 ug/L, Vitamin B12 1-1000 ug/L, Niacin 1-100 ug/L, Ascorbic Acid 1-5000 ug/L, Folinic Acid 1-100 ug/L, Liponic Acid 1-100 ug/L, Vitamin A (Acetate) 10-1000 ug/L, Pyridoxine-Hcl 1-100 ug/L, Niacinamide 1-100 ug/L, α -Tocopherol phosphate 0-1000 ug/L; and D-Glucose 100-5000 mg/L, Phenol Red 0,1-1000 mg/L, Glutathione (reduced) 0,01-10 mg/L, Na-Pyruvate 0,1-50 nM, Epidermal Growth Factor (EGF), recombinant 1-3000 ng/L, Fetal Bovine Serum (FBS), Bovine

Art Unit: 1643

Insulin (Lyophilisate) 0,1-50 mg/L and antibiotics, and by cultivation conditions such as a 0.01% to 3% oxygen atmosphere, an 0.1% to 5% carbon dioxide atmosphere, at a humidity of 100% and temperature in the range from 30 degrees C to 36.5 degrees C.

On page 6, line 1, the phrase "as specified in claim 9" has been deleted.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10-6:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen A Canella/

Primary Examiner, Art Unit 1643